Fuxman, Claudia;
Sicilia, Beatriz;
Linares, María Eugenia;
García-López, Santiago;
Sueyro, Ramiro González;
González-Lamac, Yago;
Zabana, Yamile;
Hinojosa, Joaquín;
Barreiro-de Acosta, Manuel;
Balderramo, Domingo;
Balfour, Deborah;
Bellicoso, Maricel;
Daffra, Pamela;
Morelli, Daniela;
Orsi, Marina;
Rausch, Astrid;
Ruffinengo, Orlando;
Torok, Martín;
Sambuellir, Alicia;
Novillos, Abel;
Gomollónt, Fernando;
Paula, Juan Andrés De.
Ulcerative colitis (UC) is a chronic inflammatory disease that compromises the colon, affecting the quality of life of individuals of any age. In practice, there is a wide spectrum of clinical situations. The advances made in the physio pathogenesis of UC have allowed the development of new, more effecti...
NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Commercial arrangement
There is a commercial arrangement for nivolumab. NHS organisations can get...
The Feldenkrais method is presumably preferred by social groups who generally strive to use non-drug and non-surgical interventions for preventing and treating diseases. Since chronic pain is more common in advanced age, older people are likely to be more interested in this method. This health technology...
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT‑ON (Sense4care) for remote monitoring of Parkinson’s disease....
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Commercial arrangement
There is a managed access agreement, which includes a patient access scheme, for trastuzumab derux...
Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.
This technology appraisal is for treating idiopathic pulmonary fibrosis in people with a forced vital capacity (FVC) above 80% predicted. Nintedanib...
Gartlehner, G;
Dobrescu, A;
Chapman, A;
Toromanova, A;
Emprechtinger, R;
Persad, E;
Affengruber, L;
Pieh, C;
Klerings, I;
Wagner, G.
Primary care patients and clinicians may prefer alternative options to second-generation antidepressants for major depressive disorder (MDD). To compare the benefits and harms of nonpharmacologic treatments with second-generation antidepressants as first-step interventions for acute MDD, and to compare s...
This first update alert reports the surveillance results of the living systematic review on “Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians” (1...
Next
Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.
Commercial arrangement
There is a commercial access agreement for nivolumab...
